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Abstract 
Central administration of orexin-A has been shown to activate autonomic arousal in rats, 
reliably inducing anxiety-like behaviours in the open field. To date, there has yet to be a 
study investigating the role of orexin-A in the communication of such negative affective 
state. In the current study, forty-six adult male rats were chronically cannulated and 
administered orexin-A into the medial preoptic area/anterior hypothalamic area to 
determine the effect of this neuropeptide on anxiety-like behaviour and the production of 
22 kHz aversive ultrasonic vocalizations. It was found that intracerebral administration of 
orexin-A increased autonomic arousal as measured by a significant increase in fecal boli 
output, however orexin-A did not significantly affect locomotor activity or induce 22 kHz 
calling. These data suggest that orexin-A is involved in the regulation of the autonomic 
aspect of anxiety-like behaviour but not in the vocal communication of such negative 
affect. 
Keywords: Orexin-A; Anxiety-like behaviour;  22 kHz calls; Ultrasonic 
vocalizations; Rat
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The Role of Orexin-A in Anxiety and the Emission of Ultrasonic Vocalizations in Rats 
Anxiety disorders are the most commonly diagnosed mental health issues in the 
United States and Canada (Barlow, 2002; Health Canada, 2009), and represent the second 
leading cause of visits to a physician after routine physical exams (Barlow, 2002). While 
fear is understood as an innate primary emotion that serves to alert one to a tangible 
threat and arouse the body for action, anxiety is conceptualized as a fixation on possible 
negative events in the future, leading to hypervigilance of one’s environment and 
apprehension (Barlow, 2012; 5
th
 ed; Diagnostic and Statistical Manual of Mental 
Disorders, American Psychiatric Association, 2013). Panic, an extreme and unexpected 
form of fear (Freeman & Freeman, 2012), is characterized by episodes of autonomic 
arousal accompanied by psychological ideations (such as a fear of losing control or 
imminent death) peaking within 10 minutes after onset (DSM- 5, American Psychiatric 
Association, 2013). Many who seek medical attention for unexplained medical issues 
such as heart palpitations, faintness, bowel upset, vertigo and dizziness often 
subsequently meet the criteria for an anxiety disorder (Barlow, 2002). Typified by 
excessive or persistent fear or anxiety, these disorders include separation anxiety, 
selective mutism, specific phobia, social anxiety disorder, panic disorder, agoraphobia, 
generalized anxiety disorder, substance/medication induced anxiety disorder, anxiety 
disorders due to another medical condition, and other specified anxiety disorder (DSM-5, 
2013). Once diagnosed, the symptoms of anxiety disorders are often chronic and 
recurrent for many individuals despite intervention (Barlow, 2002).  As such, it has been 
estimated that anxiety disorders cost approximately 42.3 billion dollars per year 
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(Greenberg et al., 1999) largely due to the use of health care services and loss of 
productivity and absenteeism in the workplace (Barlow, 2002). 
 
Many theories have been put forth in an attempt to explain the etiology of anxiety 
and its disorders, whether psychoanalytic, behavioural, cognitive or neurobiological 
(Freeman & Freeman, 2012). Seminal work by Donald Klein in 1959 was able to 
dissociate panic and anxiety. He was also able to show that sodium lactate and carbon 
dioxide could induce the panic, leading to the conclusion that such behaviours could 
result from the brain’s perceived lack of oxygen, or a feeling of suffocation (Freeman & 
Freeman, 2012). David Clark and Hans Eysenck expanded on this idea theorizing that 
some individuals demonstrate high baseline levels of cortical arousal matched with a 
propensity for extreme autonomic reactivity (Barlow, 2012), and experience panic due to  
catastrophically misinterpreting physiological arousal of the body as dangerous and 
potentially fatal (Freeman & Freeman, 2012).  
 
 Jeffrey Gray has speculated that the neural basis of such behaviours compose a 
‘behavioural inhibition system’ regulated by the septal area, hippocampus, and structures 
of the Papez circuit, and contributing to the individual reacting to new situations and/or 
punishment with extreme behavioural inhibition and decreased behavioural approach 
(Barlow, 2012).  Fear and panic on the other hand, are regulated by an alternate system, 
the ‘fight or flight system’, which initiates defensive aggression or escape behaviours in 
aversive situations and is mediated by the periaqueductal gray and medial hypothalamic 
control of the amygdala (Barlow, 2012). The theory of behavioural inhibition is 
10 
 
 
 
supported by research with human subjects which has shown that individuals presenting 
with behavioural inhibition show hyperactivity of the hypothalamic-pituitary-adrenal 
(HPA) axis (Tykra et al., 2006).  
 
Animal models of anxiety vulnerability are often used to study individual 
differences in trait anxiety. The Wistar Kyoto rat is a strain shown to demonstrate 
behavioural inhibition and hypervigilance, traits that are suggested by the hypervigilance-
avoidance theory to play a key role in the development of anxiety disorders (McAuley, 
Stewart, Webber, Cromwell, Servatius, & Pang, 2009). The Otsuka Long Evans 
Tokushima Fatty rat, which lacks the cholecystokinin type 1 receptor (Schroeder & 
Weller, 2010), and wild type rats selectively bred for high anxiety-related behaviour in 
the elevated plus maze (Roy, Chapillon, Jeljeli, Caston & Belzung, 2009) are also used to 
study these effects.  
 
Research with such animals and human subjects has shown that anxiety can be 
induced in some individuals through protocols that manipulate respiration (through 
exercise, hyperventilation, or CO
2 
inhalation) or by increasing autonomic arousal 
[through administration of epinephrine, isoproterenol (stimulating beta-andrenergic 
receptors), yohimbine (an alpha-andrenergic antagonist), caffeine, cholecystokinin, 
benzodiazepine antagonists, mCCP (serotonin agonist), lactate, and acetylcholine] 
(Barlow, 2012). Currently two classes of drugs have been shown to have clinical efficacy 
in ameliorating these anxiogenic effects, benzodiazepines and selective serotonin 
reuptake inhibitors (Julien, Advokat & Comaty, 2008).  
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Treatments for anxiety and its disorders target transmitter systems in the brain 
known to regulate structures of the limbic system (Julien et al., 2008). Benzodiazepines 
are a group of drugs used for the short term relief of symptoms of anxiety exerting their 
anxiolytic action by facilitating the binding of GABA to GABAA receptors, thus 
increasing inhibitory tone on structures including the amygdala, orbitofrontal cortex and 
insula. However, given the risk of dependency with the use of benzodiazepines, serotonin 
receptor antagonists are more often used in the treatment of anxiety disorders. Selective 
serotonin reuptake inhibitor (SSRI) antidepressants, 5-HT 1A agonists in particular, 
decrease neuronal activity in structures known to regulate anxiety-like behaviours (Julien 
et al., 2008). Recent research has shown that a group of neuropeptides known as orexins, 
or hypocretins, are involved in the regulation of anxiety-like behaviours and offer a new 
and exciting opportunity for anxiety research (Suzuki, Beuckmann, Shikata, Ogura, & 
Sawai, 2005). 
 
Two endogenous neuropeptides, orexin-A and orexin-B, and their two receptor 
types, OX1 receptor (OX1R) and OX2 receptor (OX2R), were identified by Sakurai and 
colleagues in 1998 (Sakurai et al., 1998).  Orexins were named after the Greek word for 
appetite (orexis), due to the fact that the mRNA precursor prepro-orexin is found 
primarily in the lateral hypothalamus which is known to regulate consummatory 
behaviour (Sakurai et al., 1998).  However, in the same year, this group of hypothalamic 
neuropeptides were discovered by De Lecea and colleagues and named hypocretins due 
to their similar amino acid structure to the incretin group of hormones (De Lecea, et al., 
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1998). It is currently estimated that orexin neurons constitute approximately 1,800 
neurons within the lateral hypothalamus (Henny & Jones, 2006). 
 
Direct innervations to orexin neurons arise from all regions of the cortex with the 
exception of the cerebellum (Yoshida et al., 2006). Primary projections to orexinergic 
neurons originate in the basal forebrain, limbic structures including the amygdala, and the 
brainstem, including the periaqueductal gray and dorsal raphe nucleus. The highest 
density of afferent connections is found in the lateral septum, the bed nucleus of the stria 
terminalis (BNST), the medial preoptic area (MPOA), and the posterior hypothalamus 
(Yoshia et al., 2006).  
 
OX1R exclusively binds orexin-A, while OX2R is non-selective for orexin-A and 
orexin-B (Sakurai et al., 1998). OX1R and OX2R are found throughout the hypothalamus,  
although OX2R receptor expression is most dense in the regions of the paraventricular 
nucleus  (CRF neurons), lateral hypothalamic area (feeding), and the tuberomammillary 
nucleus (histamine), as well as the ventral tegmental area (dopamine) and raphe nuclei 
(serotonin) (Marcus et al., 2001). OX1R mRNA has been identified primarily in the 
prelimbic and infralimbic cortices as well as the ventromedial region of the 
hypothalamus, the hippocampal formation, and the raphe nucleus, and found most 
densely in the locus coeruleus, noradrenergic cells, and cholinergic cells of the LDT 
(Marcus et al., 2001). mRNA for OX2R have been localized to the paraventricular 
nucleus of the hypothalamus, the nucleus accumbens, and cerebral cortex (Trivedi et al., 
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1998), and most abundantly in the deep layers of the cortex and areas of the basal 
forebrain including the septal nucleus and diagonal band, whose serotonergic and 
cholinergic neurons are stimulated by orexin (Marcus et al., 2001). 
 
Given the vast connections of orexin neurons throughout the brain, Yoshida et al. 
(2006) have suggested that these neurons are involved in the integration of various 
sensory and motor abilities for the promotion of behavioural arousal in response to 
disruptions to homeostatic balance. Specifically, orexinergic cells of the hypothalamus 
constitute a feedback loop with monoaminergic and cholinergic transmitter systems of the 
ascending reticular activating system to facilitate wakefulness needed to carry out various 
adaptive and appetitive behaviours (Lopez et al., 2010; Lopez-Aumatell et al., 2011; del 
Cid-Pelitero, & Garzon, 2011; Yamanaka, Muraki, Tsujino, Goto, & Sakurai, 2003). 
Additionally, inhibitory GABAergic input from ventrolateral preoptic area (VLPO) 
(Martinez et al., 2002) and the basal forebrain onto orexin neurons serve to facilitate 
sleep, while excitatory glutamatergic input results in behavioural arousal (Henny & 
Jones, 2006). These findings are supported by animal research having demonstrated that 
hypocretin-1/orexin neurons are activated in the hypothalamus when rats are awake and 
active (Yoshida et al., 2001; Martinez, Smale, & Nunez, 2002; Estabrooke et al., 2001).   
 
Orexins are also implicated in the regulation of other behaviours that serve to 
maintain homeostatic balance through the promotion of wakefulness (Yoshida, 
McCormick, Espana, Crocker, & Scammell, 2006) and motor control (Zhang et al., 
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2011), including reward-seeking (reviewed in Kodadek & Cai, 2010), sexual arousal, and 
copulatory performance (Gulia, Mallick, & Kumar, 2003). Orexins also serve to regulate 
the brain-gut axis to promote arousal and digestive functions for foraging and 
consummatory behaviour (Kotz, 2006; Baird et al., 2009; Thorpe & Kotz, 2005; reviewed 
in Kirchgessner, 2002; Bulbul, Babygirija, Zheng, Ludwig, & Takahashi, 2010).  
 
Of particular interest is evidence of the role of orexin A and the OX2R in the 
modulation of anxiety-like behaviour and activation of the HPA axis (Chang et al, 2007; 
Li et al., 2010; Nollet et al., 2011).  Administration of orexin A significantly increases 
anxiety-like behaviours (Suzuki at al., 2005), by inducing neuronal activation in 
structures of the HPA axis as evidenced by fos-like immunoreactivity in the PVN of the 
hypothalamus and central amygdaloid nucleus (Sakamoto, Yamada, & Ueta, 2004; Kuru 
et al., 2000) and increased plasma levels of stress hormones corticotrophin releasing 
factor (CRF), adrenocorticotropic hormone (ACTH), and corticosterone (Al-Barazanji, 
Wilson, Baker, Jessop, & Harbuz, 2001; Ida et al., 2000).  
 
Research indicates that orexin neurons from the LHA innervate the PVN, a 
structure with widespread connections to the extended amygdala, and widely known to be 
involved in the regulation of anxiety-like behaviour (Li et al., 2010), as well as making 
extensive efferent connections within the sympathetic nervous system (Geerling, 
Mettenleiter, & Loewy, 2003). Orexin cells have been found to constitute fifty percent of 
the neurons making multisynaptic connections from the medial preoptic nucleus/lateral 
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hypothalamus to the medial prefrontal cortex and the heart, forming a circuit regulating 
negative affect and sympathetic outflow (Krout, Mettenleiter, Karpitskiy, Nguyen, & 
Loewy, 2005).This stimulation of the HPA axis by orexin-A is modulated by CRF and 
opioid systems (Ida et al., 2000; Li et al., 2010; Johnson et al., 2010) and serves to 
maintain vigilance and attention to potentially threatening  environmental cues (Furlong, 
Vianna, Liu & Carrive, 2009), and to prepare the body for fight-or-flight (Zhang, Zhang, 
Sakurai, & Kuwaki, 2009).   
 
Anxiety can be induced in the laboratory setting in rats by stress procedures 
considered ‘natural’ or ‘unnatural’, e.g., inescapable foot shock (Rod et al., 2012), 
chronic restraint stress (Chiba et al., 2012), social-defeat/overcrowding, chronic 
subordinate colony housing (Slattery et al., 2012), the odour of predators (Masini et al., 
2010), vestibular stress (Markia, Kovacs, & Palkovits, 2008), early sibling deprivation 
(Li et al., 2008), maternal separation (Plotsky et al., 2005), anorexia (Kinzig & Hargrave, 
2010), prenatal stress (Wilson, Vazdarjanova, & Terry, 2012), caloric restriction (Levay, 
Govic, Penman, Paolini, & Kent, 2007), and postnatal exposure to methamphetamine 
(Hruba, Schutova, & Slamberova, 2012) and cocaine (Kohtz, Paris, & Frye, 2010) to 
name a few. 
 
While a clear threat to a rat, such as a predator or threatening conspecific, will 
reliably induce defensive behaviours related to fear such as defensive attack, back 
defence and flight, unspecific or potential danger will induce behaviours related to 
anxiety, such as risk assessment, vigilance, freezing behaviour and the production of 
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ultrasonic calls (Blanchard & Blanchard, 1989; Blanchard, Blanchard, Rodgers & Weiss, 
1990). Twenty-two kilohertz ultrasonic vocalizations in particular represent a measure of 
negative affective state in the rat (reviewed in Brudzynski, 2001). These aversive calls are 
used by an animal to express the anticipation of negative contact and to alarm 
conspecifics. Such alarm calls are regulated by the medial cholinoceptive strip, a group of 
structures innervated by cholinergic fibres originating from the laterodorsal tegmental 
nucleus. These structures extend rostrally through areas including the anteromedial 
hypothalamus, the preoptic area, the bed nucleus of the stria terminalis, ventral pallidum, 
and lateral septum (reviewed in Brudzynski, 2001). The ascending mesolimbic 
cholinergic system innervates these structures, and the release of acetylcholine at the 
terminals reliably initiates aversive ultrasonic vocalizations. These calls can be induced to 
activate these neurons pharmacologically by presynaptic administration of glutamate to 
the laterodorsal tegmental nucleus, or postsynaptically via application of a 
cholinomimetic to the terminal fields located throughout the medial cholinoceptive 
vocalization strip (Reviewed in Brudzynski, 2001).   
 
Administration of carbachol, an acetylcholine agonist, into the medial preoptic 
area of the hypothalamus has been shown to reliably induce 22 kHz aversive calling 
(Brudzynski, 1994). This region is densely innervated by neurons that synthesize and 
secrete orexin (Marcus et al., 2001), in addition to demonstrating high levels of orexin 
type-1 receptor expression, which bind orexin-A exclusively (Sakurai et al., 1998). 
Therefore, it is speculated that aversive calling in the rat may be modulated by 
orexingeric stimulation of the medial preoptic area.  
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The goal of the present study is to investigate the role of orexin-A on anxiety-like 
behaviour in the rat, and to determine if this neuropeptide is involved in the 
communication of negative affective state as expressed through the emission of 22 kHz 
ultrasonic vocalizations. It is hypothesized that intracerebral injection of orexin A will 
induce species-typical anxiety-like behaviour with concomitant emission of aversive 22 
kHz alarm calls.  
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2. Methods 
2.1 Animals 
Thirty-eight adult out bred male Long Evans rats (Charles River Laboratories, 
Quebec) between 275-465 g of body weight were used for this study. Animals were 
housed in Brock University’s Mammal Facility, in translucent polycarbonate cages (460 
mm × 250 mm) with dust-free corn cob bedding, a dark plastic burrow for hiding, paper 
towel for nesting and aspen blocks for enrichment. Water and standard pellet rat chow 
(Harlan, WI, USA) were available ad libitum. The housing room was temperature and 
light controlled on a 12:12 h dark-light cycle (lights on at 08:00 h). Rats were housed in 
pairs before surgery and transferred to individual cages postoperatively.Surgeries were 
performed no sooner than four days after arrival, and all rats were handled daily to 
habituate them to the experimenter.  
 
Animals were provided with veterinary care as required. All research was 
conducted in accordance with the ‘Guide to the Care and Use of Experimental Animals’ 
mandated by the Canadian Council on Animal Care (Vol.1, 2
nd
 ed; CCAC Guide to Care 
and Use of Experimental Animals, 1993), and approved by the Brock University Animal 
Care and Use (AUPP 11-09-03). 
 
2.2 Stereotaxic surgery and cannulation 
The rats were anesthetised with Isoflurane (5% induction, 2% maintenance) and 
mounted on the stereotaxic frame (David Kopf Instruments, CA, USA) under aseptic 
conditions. As the medial preoptic area (MPOA) of the hypothalamus is innervated by 
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lateral hypothalamic neurons that synthesize and secrete orexin, and demonstrates high 
levels of orexin type-1 receptor expression (Marcus, Aschkensai, Lee, Chemelli, Saper, 
Yanagisawa & Elmquist, 2001; Kolaj, Coderre & Renaud, 2008), the MPOA was the 
target site for intracerebral administration of the drug. Sixteen millimetre long stainless 
steel guide cannulae (23 gauge, Becton Dickinson & Co., NJ, USA) were implanted 
unilaterally 1.0 mm above the medial preoptic area (7.7 mm anterior, 0.5 mm lateral, 7.2 
mm ventrally from bregma) according to stereotaxic atlas (Paxinos & Watson, 1977). 
Guide cannulae were secured to the skull by stainless steel screws and dental acrylic 
(DenPlus, Longueuil, QC). A stainless steel stylet was subsequently inserted into the 
guide cannulae to prevent occlusion. After implantation of the guide cannulae, the 
incision was either closed with sterile surgical silk suture (Ethicon) or covered with 
dental acrylic, a novel technique endorsed by facility veterinary staff. 
 
Animals were given one week to recover from surgery, and handled only for regular 
cage maintenance and postoperative care. Once rats had recovered, they were habituated 
to the open field apparatus and injection procedures once per day for three days before 
commencing the study. All animals were transferred to the acoustic recording laboratory 
where they were gently handled and received mock injections, and were placed in the 
open field testing arena for 10 minutes. Experimentation was conducted during the ‘light’ 
phase and only those animals deemed to be in good health were included in the 
experiment. 
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2.3 Microinjections and drugs 
Pharmacological agents were dissolved in saline on the day of each injection, and 
administered according to a within subjects design. Drugs administered consisted of 4 µg/ 
0.5 µl of orexin A (ORX) (Abcam, Cambridge, MA) a moderate dose in relation to 
previous research(Kuru et al., 2000; Gulia et al., 2003; Li et al., 2010), or 1 µg/ 0.5 µl of 
carbamylcholine chloride (carbachol, CCh) (Sigma, St. Louis, MO). Administration of 
carbachol served as a comparison group for 22 kHz ultrasonic calling induced by orexin, 
as this acetylcholine agonist reliably induces aversive calls from the medial preoptic area 
(Brudzynski, 1994).  Rats were gently restrained during intracerebral injection to 
minimize distress to the animal and ensure quick and efficient injection. Stylets were 
removed and the injection cannulae and opening of the guide cannulae were sterilized 
with 70% alcohol before each injection. The drug or the vehicle (0.9% NaCl, Baxter 
Corp, ON, Canada) was injected (0.5 µl) through an injecting cannula (30 gauge, Small 
Parts Inc, Miami, FL), which protruded 1.0 mm below the guide cannula. A glass 
constant rate microsyringe (Hamilton Co., Reno, NV) was used to deliver the drug or 
vehicle at a rate of approximately 15 nl/s, with a period of 30 seconds between pre-
treatment and injection. Counterbalanced double injections (saline-saline, saline-
carbachol, orexin-saline, orexin-carbachol) were administered once per day with a 5 day 
wash out period between injections.   
 
2.4 Ultrasonic vocalization recording  
  All vocalizations emitted during each 10 minute post injection testing session 
were recorded via a condenser microphone (model CM16/CMPA, Avisoft Bioacoustics, 
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Berlin, Germany) that was suspended 20 cm from the floor of the testing arena. On 
average, the distance between the rat and the microphone was approximately 15 cm. 
Vocalizations were recorded using Avisoft Bioacoustics software (Avisoft Recorder 
NIDAQMX) and stored on the hard drive of a PC computer (Dell Precision 390) and later 
saved to DVD for analysis. The acoustic files were analyzed off-line using Avisoft SAS-
Lab-Pro program (with a filter of 0 - 250 kHz and FFT with resolution of 1.95 kHz). 
 
2.5 Sonographic analysis of USVs 
Twenty-two kilohertz (kHz) vocalizations typically occur in the range of 18-32 
kHz, with a mean peak frequency of 22 kHz. Alarm calls of this nature are emitted in a 
series of calls with a narrow bandwidth (1 - 6 kHz) and a long duration (300 - 2000 ms) 
(Reviewed in Brudzynski, 2001).  
 
The first and the last 20 calls recorded during the 10-minute testing session were 
analyzed for the following parameters: peak frequency (kHz), call duration (ms), and call 
bandwidth (kHz). All calls were categorized by average peak frequency as either 50-kHz 
calls (defined as 36 kHz or above), or as 22 kHz calls (defined as 35 kHz or below). Calls 
were further categorized by type as either flat or frequency modulated according to 
sonographic characteristics. Finally, the total number of 22 kHz ultrasonic vocalizations 
emitted during each testing session was counted for each rat.  
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2.6 Spontaneous locomotor behaviour, autonomic arousal 
After receiving a microinjection of drug and/or vehicle into the MPOA, rats were 
placed into a square open field (43.18 cm x 43.18 cm x 20.32 cm) Digiscan Animal 
Activity Monitor (Columbus Instruments, OH, USA) equipped with a grid of infrared 
light beams (4 beams per wall) for 10 minutes. After each test, the open field was cleaned 
with 0.5% hydrogen peroxide (Virox Technologies, Oakville, ON).  Ambulation and 
horizontal movements were electronically recorded as the number of infrared beam 
crosses.  Horizontal movements included any movement recorded other than rearing. 
Ambulation included walking bouts, i.e., when only successive infrared beams were 
broken by the animal. Autonomic arousal was assessed by the number of fecal boli 
deposited and incidence of urination produced during each 10 minute testing session.  
 
2.7 Histological injection localization 
On the last day of behavioural testing, all animals were deeply anaesthetized with 
an overdose of sodium pentobarbital (120 mg/kg). Animals were then transcardially 
perfused with 10% formalin solution, and brains removed and fixed in formalin for at 
least 48 hours. The brains were blocked and serial coronal sections (60 µm) were 
prepared using a freezing microtome (Hacker Instruments, NJ, USA). Sections were air-
dried and stained in a water solution of thionin, differentiated in three increasing 
concentrations of ethyl alcohol, then cleared with xylene. Stained sections were covered 
with Permount (Fisher Scientific, NJ, USA), cover slipped, dried and analyzed to identify 
injection sites according to the rat brain atlas (Paxinos & Watson, 1977).  
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2.8 Statistical Analysis 
Statistical comparisons were performed using repeated measured analysis of 
variance (ANOVA), chi square test of independence, or correlation, using IBM SPSS 
Statistics (IBM, Armonk, New York). F tests for simple effects, Least Squares 
Difference, and paired t-tests were used for post hoc analysis where appropriate. An alpha 
level of p ≤ 0.05 (two-tailed) was used to determine significance. Statistics for unequal 
variances and corrected degrees of freedom are reported for any analyses violating the 
assumption of homogeneity of variance. Data are presented as mean + SEM.   
Due to the experimental limitations, the resulting low and variable sample size (n) 
across injection conditions did not meet the statistical assumptions  (i.e., normality, 
homogeneity of variance, etc.) typically required of parametric statistics. As a result, all 
conclusions derived from the conducted parametric statistics should be interpreted with 
caution. In light of these stated limitations, the parametric tests utilized provide an 
estimation of the probability that these effects exist outside of the collected sample.  
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3. Results 
3.1 Cannula placement 
The target site for injector cannula placement was the MPOA. Injection sites were 
localized on the frontal stereotaxic plane as either MPOA, or anterior hypothalamic area 
(AHA). All other locations were grouped together and treated as a negative control 
(OUT). In total, cannulae placements were localized as follows: MPOA (n = 7), AHA (n 
= 6), OUT (n = 15), and not available N/A (n = 18), see Figure 1a & 1b. Brain slice 
preparations for 18 animals were damaged or compromised and cannulae placements 
could not be localized, therefore cannulae placements are not available.  
 
Figure 1a. Intracerebral localization of injection sites on coronal brain cross-sections 
(interaural 8.16 mm, Bregma -.084 mm) according to Paxinos & Watson (2005). 
Black circles indicate those animals that did not vocalize subsequent to intracerebral 
administration of carbachol. Rats with injections sites localized anterior/posterior to 
the hypothalamic region are not shown.  Abbreviations: BSTMP: Bed Nucleus of the 
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Stria Terminalis, Ch: Optic Chiasm, CPu: Caudate/Putamen, GP: Globus Pallidus, 
MPOA: Medial Preoptic Area.  
 
 
Figure 1b. Intracerebral localization of injection sites on a coronal brain cross section 
(interaural 7.68 mm, Bregma -1.32 mm) according to Paxinos & Watson (2005). 
Green circles indicate those animals that vocalized subsequent to intracerebral 
administration of carbachol. Rats with injections sites localized anterior/posterior to 
the hypothalamic region are not shown. Abbreviations: AHA: Anterior Hypothalamic 
Area, BSTMPL: Bed Nucleus of the Stria Terminalis Posterolateral, CPu: 
Caudate/Putamen, GP: Globus Pallidus, IC: Internal Capsule.  
 
3.2 Effects of microinjections of orexin-A and carbachol on the number of 22 
kHz aversive calls.  
Descriptive statistics for average number of 22 kHz ultrasonic vocalizations 
induced by intracerebral injections indicate that intracerebral administration of saline 
and orexin did not induce 22 kHz aversive ultrasonic calls at the studied dose, while 
carbachol did induce such vocalizations.   
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Table #1 shows means and standard deviations of the average number of 22 kHz 
ultrasonic vocalizations as a function of injection conditions, and Figure 2 depicts 
these data in graphical form. 
 
Table 1. 
Descriptive statistics of the average number of 22 kHz ultrasonic vocalizations induced 
as a function of drug injection condition.  
Injection Condition  
Mean Number of 
Calls (SE) 
N 
Sal-Sal  0 (0) 25 
Sal-Orx  0 (0) 26 
Sal-CCh  4.79 (2.77) 25 
Orx-CCh  0.08 (0.08) 10 
Note: Sal: saline; Orx: orexin-A; CCh: carbachol 
 
 
Figure 2. Number of 22 kHz ultrasonic vocalizations induced by intracerebral injection 
(saline-saline, orexin-saline, saline-carbachol, and orexin-carbachol). The data show that 
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orexin does not appear to induce 22 kHz ultrasonic vocalizations; carbachol-induced 
vocalizations and response may be inhibited by pre-treatment of orexin. 
 
The acoustic parameters of 22 kHz ultrasonic calls, or alarm calls, that were 
induced by intracerebral administration of saline-carbachol were found to be species 
typical. Table 2 provides the descriptive statistics of average call parameters of the 22 
kHz ultrasonic vocalization induced by intracerebral administration of saline-carbachol. 
Figure 3 provides sample sonograms of 22 kHz ultrasonic vocalizations induced by 
injection of saline-carbachol. The 22 kHz ultrasounds had a stable sound frequency 
lasting approximately 1000 ms, with a very narrow bandwidth.  
Table 2.  
Descriptive statistics of call parameters of the 22 kHz ultrasonic vocalization induced by 
intracerebral administration of saline-carbachol.  
 
Average 
Number of 
Calls Emitted 
(n) 
Duration 
(Seconds) Bandwidth (kHz) Peak Frequency (kHz)  
Mean 31 1.74 4.6 22.13 
Note: Five animals out of 34 emitted 22 kHz ultrasonic vocalizations subsequent to 
administration of the saline-carbachol, while the remaining 29 animals did not vocalize 
after such administration.  
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Figure 3. Examplary sonograms of 22 kHz ultrasonic vocalizations induced by 
intracerebal injection of saline-carbachol. Time scale on the x-axis is in seconds, and the 
y-axis in kilohertz (0 - 125 kHz). The peaks in the rectangles on the left hand side 
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indicate peak frequencies. The duration of these vocalizations is from 0.8 to 1.5 seconds, 
with the fundamental frequency 24 - 25 kHz. 
 
3.3 Effects of microinjection of orexin-A and carbachol into the MPOA and AHA on 
the number of 22 kHz aversive vocalizations. 
The average number of 22 kHz ultrasonic vocalizations induced by intracerebral 
injection was further analyzed as a function of injection localization. Table 3 provides the 
means and standard errors of the number of 22 kHz ultrasonic vocalizations induced by 
intracerebral injections; Figure 4 shows these data in graphical form. These data indicate 
that intracerebral administration of orexin-A and saline did not induce aversive calls. 
Carbachol, on the other hand, did induce 22 kHz calls, but only when administered to the 
medial preoptic area or anterior hypothalamic area.  
Table 3.  
Descriptive statistics of mean of number of 22 kHz ultrasonic vocalizations induced 
by orexin, carbachol and saline control as a function of localization.   
 MPOA  AHA  OUT  
Injection 
Condition  
Mean # of 
Calls  (SE) n  
Mean # of 
Calls (SE)  n 
Mean # of 
Calls (SE) n  
Sal-Sal  0 (0)  6  0 (0)  6  0 (0)  10  
Orx-Sal  0 (0)  8  0 (0)  5  0 (0)  11  
Sal-CCh  4.0 (4.0)  8  20.2 (16.08)  5  0 (0)  12  
Orx-CCh  0 (0)  3  0 (0)  3  0 (0)  4  
Note: MPOA: medial preoptic area; AHA: anterior hypothalamic area; OUT: any other 
location outside of the MPOA or AHA. 
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Figure 4. Number of ultrasonic vocalizations induced by intracerebral injection as a 
function of injection localization. These data demonstrate that saline and orexin did not 
induce 22 kHz ultrasonic calls. Carbachol does induce aversive calls, but only when 
administered to MPOA and AHA, although this difference was not found to be 
significant (p > .05). 
 
An independent measures t-test was conducted to determine the effect of 
localization on carbachol induced 22 kHz vocalizations. It was found that there was not a 
significant effect of localization on the number of calls induced by carbachol, t (11) = -
1.21, p = .25. Therefore, saline-carbachol does appear to induce more 22 kHz ultrasonic 
vocalizations above other treatment groups, although in this case the effects of this drug 
on 22 kHz ultrasonic calling rate are not significantly different when administered to the 
MPOA or AHA.  
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3.4 Effects of microinjection of orexin-A and carbachol on autonomic arousal 
Urination 
A chi-square test of independence was conducted to determine the effect of 
intracerebral injection on urination (see Table 4 for descriptive statistics). It was found 
that urination and injection condition are independent of one another, χ2  (3) = 4.21, p = 
.24. Therefore, the incidence of urination does not depend on type of agent administered 
to the brain (orexin-A, carbachol, or saline - see Figures 5a and 5b). Although injection 
condition is independent of urination, examination of the standardized residuals indicates 
a higher incidence of urinating animals injected with orexin-saline than the others, 
whereby the observed occurrence of urination is twice that of the expected rate.  
Table 4.  
Percentage of incidence of urination in rats as a function of intracerebral injection 
condition.  
Urination  Sal-Sal Orx-Sal Sal-CCh Orx-CCh All Injection 
Conditions 
NO  94.6% 83.8% 94.3% 94.6% 91.8% 
YES  5.4% 16.2% 5.7% 5.4% 8.2% 
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Table 5. 
Results table for Chi-Squared test of independence of urination as a function of injection 
condition 
 
 
 
Sal 
-Sal 
Orx-
Sal 
Sal-
CCh 
Orx-
CCh 
 
No Count 35 31 33 35 
 
Expected 
Count 
 
34.0 34.0 32.1 34.0 
 Residual 1.0 -3.0 0.9 1.0 
 Std. Residual 0.2 -0.5 0.2 0.2 
Yes Count 2 6 2 2 
 
Expected 
Count 
 
3.0 3.0 2.9 3.0 
 Residual -1.0 3.0 -0.9 -1.0 
 Std. Residual -0.6 1.7 -0.5 -0.6 
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Figure 5a. Number of animals urinating as a function of intracerebral injection condition. 
 
 
Figure 5b. Percent of animals urinating after intracerebral injection of drug.  
 
A chi-square test of independence was conducted to determine the effect of injection 
localization on urination. It was found that urination and localization are independent of 
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one another, χ2 (2) = .58, p =  .75. Therefore, the incidence of animal urination did not 
depend on where the orexin, carbachol, or saline control was administered in the brain.  
 
Defecation 
A mixed model 3 (localization [MPOA, AHA, OUT]) x 3 (injection condition [saline-
saline, orexin-saline, saline-carbachol) ANOVA was conducted to determine the effect of 
intracerebral injection condition and injection localization on the number of fecal boli 
produced in the open field (see Table 6 for descriptive statistics). Results indicate a 
significant main effect of condition, F (2, 44) = 3. 47, p = .04, but no main effect of 
localization, or interaction between localization and injection condition. Table 7 presents 
the ANOVA results and Figure 6 provides a graphical depiction of the data.  
 
Three repeated measures t-tests were conducted to examine the main effect of 
injection condition on defecation. Results indicate that the number of fecal boli produced 
by intracerebral administration of orexin-saline and saline-carbachol are significantly 
different from that of saline-saline (t (36) = -2.16, p = .04, t (34) = 3.67, p = .001 
respectively). Intracerebral administration of orexin-saline and saline-carbachol induced a 
higher rate of defection than the saline control. However, there was no significant 
difference between the number of fecal boli produced by injection of orexin or carbachol, 
t (34) = - 1.21, p = 0.24.  
 
Overall, it can be seen that orexin and carbachol administered intracerebrally 
significantly increased the number of fecal boli deposited above saline. 
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Table 6. 
Descriptive statistics of the average number of fecal boli produced in the open field after 
administration of orexin, carbachol and saline control as a function of localization 
Injection Condition Localization Mean SE N 
Sal-Sal  MPOA  0.00 0.00 8 
 AHA  0.00 0.00 6 
 OUT  0.00 0.00 11 
Orx-Sal  MPOA  0.00 0.00 8 
 AHA  1.83 3.13 6 
 OUT  1.27 2.87 11 
Sal-CCh  MPOA  .63 1.41 8 
 AHA  1.00 2.00 6 
 OUT  1.27 1.74 11 
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Table 7. Results of mixed model 3 (localization) x 3 (injection condition) ANOVA 
conducted to determine the effect of intracerebral injection and injection localization on 
the number of fecal boli produced in the open field 
 df F ŋ P 
Within Effects 
 
    
 Injection Condition 
 
2 3.47 .14 .04 
 Injection Condition X 
Localization 
 
4 0.82 0.07 0.52 
 Error 
 
44    
Between Effects 
 
    
 Localization 
 
2 0.87 0.07 0.43 
 Error 
 
22    
Note: * Indicates significant difference from saline control, p < 0.05.  
 
 
Figure 6. Average number of fecal boli produced in the open field after intracerebral 
injection of orexin, carbachol and saline control as a function of localization. 
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Overall Arousal 
A chi-square test of independence was conducted to determine the effect of 
injection condition on overall autonomic arousal (urination: yes/no + defecation: yes/no). 
Results indicate that overall arousal is dependent on injection condition, χ2  (6) = 18.22, p 
= .006. Therefore, overall autonomic arousal in the rats as measured by incidence of 
urination and/or defecation depends on the drug administered intracerebrally to the brain. 
Analysis of the standardized residuals indicates that a greater number of animals 
intracerebrally injected with saline-carbachol were found to urinate or defecate than 
would be expected (std. residual = 2.7), as did the administration of orexin-saline injected 
animals (std. residual = 1.2 - See Table 8).  
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Table 8. 
Results of chi-square test of independence of overall arousal as a function of injection 
condition.  
 
 
 
Sal 
-Sal 
Orx-
Sal 
Sal-
CCh 
 
No 
Urination 
or 
Defecation 
Count 34 27 20  
 
Expected 
Count 
 
28.9 28.9 27.3  
 Std. Residual 
1.0 -.4 -1.4  
Urination 
or 
Defecation 
Count 3 7 13  
 
Expected 
Count 
 
6.6 6.6 6.2  
 Std. Residual 
-1.4 .2 2.7  
Both 
Urination 
and 
Defecation 
Count 0 3 2  
 
Expected 
Count 
 
1.5 1.5 1.4  
 Std. Residual 
-1.2 1.2 .5  
Note: No urination or defecation: rat did not urinate or defecate in open field subsequent 
to intracerebral administration of drug.  
 
3.5 Locomotor behaviour 
Horizontal Movement 
A mixed model 3 (localization [MPOA, AHA, OUT]) x 3 (injection condition 
[saline-saline, orexin-saline, saline-carbachol) ANOVA was conducted to determine the 
effect of injection condition and localization on horizontal movement (# of infrared beam 
crosses - see Table 9 for descriptive statistics). Sphericity could not be assumed for 
condition (Mauchly’s W (2) = .32, p = .06), therefore the Greenhouse-Geisser correction 
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to degrees of freedom was applied. Results of the ANOVA (see Table 10) indicate that 
there is not a significant main effect of injection condition, F
G-G
 (1.19, 7.15) = .05, p = 
.86. Equal variances are assumed for localization (Levene’s test p values > .05). Results 
indicate that there was not a main effect of localization, F (2, 6) 1.52, p = .29. There was 
no significant interaction between injection condition and localization, F
G-G 
(2.38, 7.15) = 
.23, p = .83. Although the effect of injection condition on horizontal movement was not 
significant, it was observed that rats administered saline-orexin to the AHA produced the 
lowest rate of horizontal movement. Figure 8 depicts these results below.  
Table 9.  
Descriptive statistics of horizontal movement following injection of drug as a function of 
localization. 
Injection Condition 
Localization Mean SE n 
 Sal-Sal  MPOA 2168.00 624.982 4 
   AHA 1610.00  1 
   OUT 1888.00 328.894 4 
 Orx-Sal  MPOA 2093.25 702.169 4 
   AHA 1487.00  1 
   OUT 2013.25 529.290 4 
Sal-CCh  MPOA 2284.50 173.667 4 
   AHA 1312.00  1 
   OUT 1816.25 654.688 4 
Note: Mean represents that average number of infra-red light beam crosses 
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Table 10. 
 Results of mixed model 3 (localization) x 3 (injection condition) ANOVA to determine the 
effect of injection condition and localization on horizontal movement 
 df F ŋ P 
Within Effects 
 
    
 Injection Condition 
 
1.44 0.42 0.05 0.60 
 Injection Condition X 
Localization 
2.88 0.72 0.14 0.55 
 Error 
 
12.97    
Between Effects 
 
    
 Localization 
 
2 9.31 0.67 .01 
 Error 
 
9    
Note: * Indicates significant difference from saline control, p < 0.05. 
 
0.00
500.00
1000.00
1500.00
2000.00
2500.00
3000.00
MPOA AHA OUT MPOA AHA OUT MPOA AHA OUT
SALINE-SALINE  SALINE-OREXIN SALINE-CARBACHOL
Injection Condition
R
a
te
 o
f 
H
o
ri
z
o
n
ta
l 
M
o
v
e
m
e
n
t
 
Figure 7. Rate of horizontal activity for each injection condition as a function of injection 
localization. The rate of horizontal activity is expressed in number of broken light beams. 
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Ambulation 
A mixed model 3 (localization [MPOA, AHA, OUT]) x 3 (injection condition 
[saline-saline, orexin-saline, saline-carbachol) ANOVA was conducted to determine the 
effect of injection condition and injection localization on ambulation (see Table 11 for 
descriptive statistics).  Results of the ANOVA indicate that there is a main effect of 
localization, F (2, 9) = 8.47, p = .01 (see Table 12). A LSD post-hoc analysis was 
conducted to follow up this effect and produced significant differences between AHA and 
MPOA, and AHA and OUT (p < .05). Rates of ambulation were lower in those rats 
intracerebrally injected into the AHA compared to the MPOA and OUT, as seen in Figure 
8.   
Although there was no significant main effect of injection condition, nor an 
interaction, it was observed that, similar to the horizontal movement results reported 
above, rats injected with saline-orexin had the lowest rate of ambulation compared to 
saline-saline and saline-carbachol when they were administered into the AHA. This 
observation may be important since ambulation represents better locomotor progression 
(walking) as compared to general activity of the organism (e.g., licking and grooming), 
and may, therefore, be a more meaningful indicator of behavioural inhibition and 
decreased locomotor behaviour. 
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Table 11. 
Descriptive statistics of rate of ambulation following administration of orexin, carbachol, 
and saline control as a function of localization.  
Injection Condition  Localization Mean SE n 
Sal-Sal  MPOA 1747.00 265.120 4 
 AHA 854.00 427.264 3 
 OUT 1199.00 269.985 5 
Orx-Sal  MPOA 1644.50 248.517 4 
 AHA 389.00 389.000 3 
 OUT 1604.00 161.313 5 
Sal-CCh  MPOA 1855.50 63.212 4 
         AHA            854.00           419.508                    3  
 OUT 1589.00 617.499 5 
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Table 12. 
Results of mixed model 3 (localization) x 3 (injection condition) ANOVA was conducted 
to determine the effect of injection condition and cannula localization on ambulation 
 df F ŋ P 
Within Effects 
 
    
 Injection Condition 
 
2 0.49 0.05 0.62 
 Injection Condition X 
Localization 
4 0.62 0.12 0.66 
 Error  
 
18    
Between Effects 
 
    
 Localization 
 
2 8.47 0.65 .01* 
 Error 
 
9    
Note: * Indicates significant difference as compared to the saline control, p < 0.05. 
 
Four one-way ANOVAs were conducted to further examine the effect of injection 
localization on ambulation for each injection condition. Results of the ANOVA indicate a 
significant effect of localization for saline-carbachol and orexin-saline, F (2, 13) = 4.64, p 
= .03, and F (2, 11) = 6.08, p = .02 respectively.  A LSD post-hoc analysis was conducted 
to follow up the significant effect of saline-carbachol and orexin-saline on ambulation, 
and indicated a significant difference between AHA and MPOA and AHA and OUT (p < 
0.5).  Therefore, when rats were injected with saline-carbachol and saline-orexin into the 
AHA, there is a significant decrease in the rate of ambulation compared to those injected 
into the MPOA and OUT. 
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Figure 8. Rate of ambulation for each injection condition as a function of cannula  
location.  Ambulation is expressed in the number of broken light beams.  
 
3.6 Correlation between anxiety-like behaviours expressed by the number of fecal 
boli produced. 
As an increased number of fecal boli deposited concomitant with reduced 
locomotor behaviour may be indicative of anxiety-like behaviour, correlational analyses 
were conducted. It was found that there was no significant correlation between the 
number of fecal boli produced and the rate of ambulation for the saline control, г2 = 0.54 
p > .05, orexin-saline, г2 = - 0.16 p > .05, or saline-carbachol, г2 = 0.36 p > .05. Nor were 
there found to be significant correlations between the number of fecal boli produced and 
horizontal activity for the saline control, г2 = 0.57 p > .05, orexin-saline, г2 = - 0.15  p > 
.05, or orexin-carbachol, г2 = 0.36 p > .05. 
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4. Discussion 
This study shows that intracerebral administration of orexin-A significantly 
increases autonomic arousal in the rat, as measured by increased fecal boli output. The 
current results are congruent with previous work demonstrating that administration of 
orexin-A stimulates colonic motility in the rat in a dose dependent manner (Nozu et al., 
2011). The number of fecal boli deposited is used as an effective measure of 
emotionality, particularly autonomic arousal and anxiety in rats (Broadhurst, 1957). 
Stress has been shown to dysregulate the brain-gut axis and stimulate contraction of the 
colon and increase fecal output (Liang, Luo, Liu, Cao, & Xia, 2012; Monnikes, Schmidt, 
Tebbe, Bauer, & Tache, 1994). Consistent with these reactions, our results indicate that 
central administrations of orexin-A did activate sympathetic activity indicative of anxiety.   
 
Despite this increase in defecation in response to administration of orexin-A, there 
was no negative, and expected, correlation between orexin-A administration and overall 
autonomic arousal or locomotor behaviour, typical of anxiety-like defensive behaviour 
(Williams & Russell, 1972). Although orexin-A injected animals showed a tendency to 
decrease locomotor behaviour, this effect did not reach significance. Taken with the 
increases in autonomic arousal, these data suggest that an aversive state and defensive 
behaviour were induced. As it has been found that defecation in the open field correlates 
with levels of corticosterone, but not consistently with overall locomotor behaviour 
(Gentsch, Lichtsteiner, & Feer, 1981; Pradhan & Arunasmitha, 1991), or ambulation 
(Pare, 1964; Russell, 1973), this study will rely on the significant increase in fecal boli 
output as a reliable marker of anxiety and recruitment of the HPA axis.  
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Alternatively, it may be speculated that animals remained active after the 
administration of orexin-A and that this behaviour reflected orexinergic promotion of 
wakefulness (Lopez et al., 2010; Lopez-Aumatell et al., 2011; del Cid-Pelitero & Garzon, 
2011; Yamanaka et al., 2003), activation the HPA axis (Li, et al., 2010), increased 
postural muscle tone (Takakusaki et al., 2005), and sympathetic outflow (Geerling, 
Mettenleiter, & Loewy, 2003; Krou et al., 2005) relevant for preparation for fight-or-
flight behaviours.  Research with nocturnal and diurnal animals support such a link 
between orexin-A and increased locomotor behaviour, as it has been found that this 
neuropeptide stimulates midbrain motor areas to sustain muscle tone and promote high 
levels of locomotor behaviour during wakefulness (Takakusaki et al., 2005; 
Mileykovskiy, Kiyashchenko, & Siegel, 2002). However, the observation of the tendency 
for decreased locomotor activity in our study would imply that intracerebral 
administration of orexin-A produced localized activation of the medial preoptic/anterior 
hypothalamic areas. 
 
Measurement of stress hormone corticosterone (Lim, et al., 2011) and more 
sophisticated measures of anxiety, like the elevated plus maze (Pawlak, Karrenbauer, 
Schneider, & Ho, 2012), light/dark box (Ramos, Pereira, Martins, Wehrmeister, & Izídio, 
2008), open space (Ennaceur, Michalikova, & Chazot, 2006),  and locomotor behaviour 
(center field versus thigmotaxis) (Fernandes et al., 1999; Mallo et al., 2007) could be 
used in the future to correlate rates of defecation with anxiety-like behaviour induced by 
orexin-A to better understand behaviour observed after such administration.  
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Although orexin-A did have an effect on autonomic measures of anxiety, it did 
not induce 22 kHz ultrasonic vocalizations. These ultrasounds are an antipredator 
adaptation, functioning as an alarm signal directed to the members of the social group 
about an approaching predator or potential threat (Brudzynski, 2001; Blanchard & 
Blanchard, 1989). Such high-pitched calls are produced when air is forced through the 
constricted vocal folds creating a whistle-like effect. This higher order defensive 
behaviour allows rats to communicate in the ultrasonic range, largely undetectable by 
predatory animals above the burrow system (Brudzynski, 2001; Litvin, Blanchard & 
Blanchard, 2007).  
 
Twenty-two kHz ultrasonic vocalizations represent a reliable measure of negative 
affect in the rat, reflecting states of anxiety in anticipation of possible threats to the 
individual or the greater colony (Litvin et at., 2007; reviewed in, Brudzynski, 2013). 
Alarm calls are unambiguously interpreted by all rats as a sign of warning, and induce 
behavioural inhibition and freezing in the receiving animals (Brudzynski, 2013). These 
calls serve as an ethological transmitter or ethotransmitter which represents a species-
specific signal of negative affect and anxiety.  
 
This study used an injection dosage of 0.5 µg of orexin-A which is a relatively 
moderate dose as compared to other research studies, having administered between 0.3 
µg to 30 µg of the drug (Kuru et al., 2000; Gulia et al., 2003; Li et al., 2010). Since 
orexinergic neurons increase excitability by depolarizing postsynaptic receptors, as well 
as exciting glutamatergic input into the lateral hypothalamus (Kolaj et al., 2008), it could 
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be speculated that  orexin-A is not involved in the direct initiation of ultrasonic 
signalling. For example, unpublished data from our lab show that administration of 
carbachol pre-treated with a dose of orexin less than 0.05 µg resulted in unchanged 22 
kHz ultrasonic calling, and indicates that the dose of orexin-A applied in the current study 
being 10 times higher could have inhibited the aversive calling. Administration of orexin-
A in a dose dependent manner could further clarify the relationship between orexin-A and 
the communication of negative affect.  
 
The present data may be indicative of the influence orexin-A may have on the 
hypothalamic/preoptic area and its ability to regulate internal homeostatis, sympathetic 
control, and wake-promoting physiological functions necessary to carry out defensive 
behaviour, while not stimulating the medial cholinoceptive vocalization strip. This 
collective group of structures constitutes of all of the areas of the midbrain and forebrain 
that are cholinergically innervated by the ascending cholinergic system originating from 
the laterodorsal tegmental nucleus (Brudzynski, 2001; 2013).  As animals did not 
vocalize after administration of orexin-A, our data indicate that postsynaptic application 
of orexin-A to the terminal fields of the medial cholinoceptive vocalization strip does not 
activate cholinergic neurons involved in the communication of negative affect.   
 
Future directions for research will include further investigation into a potential 
role of orexin-A in the control of ultrasonic vocalizations. More refined measures of 
autonomic arousal indicative of anxiety, including cardiorespiratory response (Zhang et 
al., 2009), and stress hormones (Viau, Sharma, & Meaney, 1996), could be used to 
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correlate observed increases in fecal boli output and urination with decreases in 
ambulation after administration of orexin-A. These measures could also be used to 
examine correlations with ultrasonic calling rate as a means to study the role of orexin-A 
in the communication of negative affective state.  
 
 
5. Conclusions 
As hypothesized, this study demonstrates that central administration of orexin-A 
may activate anxiety-like behaviours and autonomic arousal in the rat indicative of 
negative affect and a defensive state. However, under the present conditions, orexin-A 
does not appear to be involved in the activation of the medial cholinoceptive vocalization 
strip for the communication of such negative affective state via the emission of 22 kHz 
ultrasonic vocalizations.  
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Rat Weights and Injections Administered 
   
I.C INJECTION CONDITION 
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PRESURGI
CAL 
WEIGHT 
(GRAMS) 
DECEA
SED 
REMOVED 
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STUDY 
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ORX-
CAR
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SAL-
CAR
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SAL
-
SAL 
ORX-
SAL 
RMA1 306 
  
OUT 
    
RMA2 362 
  
AHA 
 
7 
  
RMA3 319 
  
OUT X X 
  
RMA4 343 
  
OUT X X 
  
RMA5 342 
  
OUT 
    
RMA6 437 
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X 
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RMA7 471 
  
OUT X 
  
X 
RMA8 403 
  
MPOA 
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RMA9 397 
  
AHA X 
 1
8 
  
RMA10 413 
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 3
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X 
RMA12 465 
  
AHA 
    
RMA13 315 YES 
  
X X X X 
RMA14 340 
  
AHA X 
  
X 
RMA15 327 
  
OUT 
  
X X 
RMA16 320 YES 
 
OUT X X X X 
RMA17 320 
  
OUT X 
 
X X 
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65 
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